Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects of anifrolumab in Chinese adults aged 18 to 70 with active moderate to severe systemic lupus erythematosus SLE. The study aims to describe clinical outcomes focusing on remission and evaluates a systematic approach to reduce glucocorticoid GC use to minimize exposure. This phase 3b, open-label, single-arm trial collects safety, efficacy, and patient-reported outcomes in this population following current standard-of-care guidelines. Participants will receive a fixed intravenous dose of anifrolumab administered via infusion pump over at least 30 minutes every 4 weeks for a total of 13 doses from Week 0 to Week 48, alongside their stable standard treatments, which may include glucocorticoids, antimalarials, or immunosuppressants. The dosing schedule requires at least 14 days between doses, with the primary evaluation taking place at Week 52. During the study, participants will undergo regular assessments including disease activity indices, joint and skin evaluations, laboratory tests, and quality-of-life questionnaires at multiple timepoints up to Week 52. Researchers will monitor remission rates, glucocorticoid tapering success, flare rates, immune markers, and safety parameters. The total study duration for each participant is approximately one year, with detailed evaluations to understand the treatments impact on disease control and steroid reduction.
Actively Recruiting
Researchers are evaluating the efficacy and safety of torvutatug samrotecan, alone or combined with bevacizumab, compared to standard of care as maintenance treatment for participants with platinum-sensitive relapsed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. This Phase III study aims to improve treatment options after relapse with a focus on progression-free survival. Participants are randomly assigned to receive either intravenous torvutatug samrotecan alone or with bevacizumab, or to observation or bevacizumab alone as the comparator. Those assigned to bevacizumab must have previously received at least three cycles of the drug combined with platinum-based chemotherapy during their induction phase. The study includes a 5-year follow-up to assess long-term outcomes. During the trial, participants will undergo regular monitoring including assessments of progression-free survival, overall survival, subsequent therapy use, quality of life, and adverse events graded by standard criteria. Archival tumor samples are collected for analysis, and participants will be followed for up to approximately five years to evaluate treatment effects and safety. The study is conducted by AstraZeneca and includes adult women with confirmed high-grade epithelial ovarian or related cancers.